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SUMMARY. The 2004 Asian H5N1 epizootic outbreak indicates the urgent need for vaccines against highly pathogenic avian
influenza (HPAI) virus. The manufacture of inactivated whole-virus vaccines from HPAI viruses by traditional methods is not
feasible for safety reasons as well as technical issues. The low pathogenic avian influenza A/wild bird feces/CSM2/02 (H5N3) virus
was used as a heterologous neuraminidase vaccine, and HPAI A/CK/Korea/ES/03 (H5N1) virus was used as a homologous
neuraminidase vaccine. Protection efficacy of both vaccines was evaluated by clinical signs, mortality rates, and virus shedding from
oropharynx and cloaca of vaccinated chickens after challenge with HPAI A/CK/Korea/ES/03 (H5N1) virus. One dose of 128
hemagglutinin (HA) homologous H5N1 vaccine induced 100% protection in mortality and prevented viral shedding completely
after lethal dose virus challenge, whereas one dose of 64 HA unit of heterologous H5N3 vaccine only induced 50% protection in
mortality, and it did not prevent viral shedding. However, two doses at a 3-wk interval of 64 HA unit of heterologous H5N3
vaccine as well as one dose of 1024 HA unit of heterologous H5N3 vaccine induced 100% survival rate and could prevent viral
shedding completely. Furthermore, we could differentiate the sera of infected birds from those of vaccinated birds by indirect
immunofluorescent antibody test. These results suggest that heterologous neuraminidase H5N3 vaccine could be a useful tool for
the control of H5N1 HPAI epidemic in poultry.
RESUMEN. Nota de Investigación—Efecto en pollos de vacunas homólogas y heterólogas de neuraminidasa contra el virus de
influenza aviar H5N1 de alta patogenicidad.
La epizootia Asiática del año 2004 indica la necesidad urgente de vacunas contra influenza aviar de alta patogenicidad. La
elaboración por los métodos tradicionales de vacunas inactivadas preparadas con virus completos a partir de virus de alta
patogenicidad no es viable, tanto por razones de seguridad como por aspectos técnicos. El virus de influenza aviar de baja
patogenicidad A/Wild bird feces/CSM2/02 (H5N3) se utilizó como una vacuna heteróloga de neuraminidasa y el virus de influenza
aviar de alta patogenicidad A/CK/Korea/ES/03 (H5N1) se utilizó como una vacuna homóloga de neuraminidasa. Se evaluó la
eficacia de la protección mediante la observación de signos clı́nicos, la tasa de mortalidad y la diseminación viral desde la orofaringe y
cloaca de aves vacunadas posteriores a un desafio con el virus de influenza aviar de alta patogenicidad A/CK/Korea/ES/03 (H5N1).
Una dosis de la vacuna homóloga H5N1 con un tı́tulo de 128 unidades hemoaglutinantes indujo 100% de protección en mortalidad
y previno por completo la diseminación del virus luego de una dosis letal del virus de desafı́o, mientras una dosis con 64 unidades
hemoaglutinantes de la vacuna heteróloga H5N3 solo indujo un 50% de protección en mortalidad y no previno la diseminación
viral. Sin embargo, dos dosis con 64 unidades hemoaglutinantes de la vacuna heteróloga H5N3 con un intervalo de tres semanas, ası́
como una dosis con 1024 unidades hemoaglutinantes de la vacuna heteróloga H5N3 indujeron una tasa de supervivencia del 100% y
pudieron prevenir por completo la diseminación viral. Ası́ mismo, se pudo diferenciar el suero de las aves infectadas del de las aves
vacunadas mediante la prueba de inmunofluorescencia indirecta para anticuerpos. Estos resultados sugieren que la vacuna heteróloga
de neuraminidasa H5N3 puede ser una herramienta útil en el control de la epidemia de influenza aviar de alta patogenicidad H5N1
en las aves domésticas.
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Abbreviations: AI ¼ avian influenza; ECE ¼ embryonated chicken egg; EID ¼ embryo infectious dose; HA ¼ hemagglutinin;
HI ¼ hemagglutination inhibition; HPAI ¼ highly pathogenic avian influenza; IFA ¼ indirect fluorescent antibody; NA ¼
neuraminidase; PCR ¼ polymerase chain reaction; SPF ¼ specific pathogen free; TCID50 ¼ 0% tissue culture infective dose
During December 2003 and March 2004, South Korea had
experienced an epidemic of highly pathogenic avian influenza (HPAI)
caused by a type A influenza virus of the H5N1 subtype. In total, 19
domestic poultry farms (10 chicken farms and nine duck farms) were
infected with the virus. Control measures included the depopulation
of all poultry within a 3-km radius protection zone (stamping out),
quarantines, disinfection, movement restrictions, and surveillance.
Approximately 5 million chickens and ducks were slaughtered and
buried. At that time, the use of vaccines in such emergences was
limited in South Korea. The main reason for vaccination bans was
that vaccine-induced antibodies could interfere with serologic sur-
veillance and epidemiological studies.
Influenza vaccination has been widely practiced to reduce the
incidence of clinical disease in poultry, and in some cases it has been
used as part of an avian influenza (AI) eradication strategy (8).
Recently, the vaccination to HPAI in poultry has been increasing in
China, Italy, Mexico, Pakistan, and other countries (1,2,4,6,7).
Differentiation of infected from vaccinated animals strategies have
been proposed to overcome impediment of AI vaccinationDCorresponding author.
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(1,3,9,10). Recently, there is a possibility of the risk of re-entry
H5N1 HPAI to South Korea because of the recent Asian H5N1
epizootic outbreak. Because the use of highly pathogenic H5N1
strains has safety restrictions, the H5N3 virus with heterologous
neuraminidase (NA) capable of evoking cross-reactive immunity to
the H5N1 HPAI virus was investigated. Vaccination seems to
remain the principal means of combating pandemic influenza.
MATERIALS AND METHODS
Viruses and vaccines. The A/CK/Korea/ES/03 [H5N1](CK/Kr/
ES/03) strain was isolated from chickens from the first infected case of
HPAI in South Korea in 2003, and the other A/wild bird feces/Korea/
CSM2/02 [H5N3] (Wbf/Kr/CSM2/02) strain was isolated from wild
bird feces during active surveillance of migratory birds in 2002. Viruses
were propagated in 10-day-old specific pathogen free (SPF) embryo-
nated chicken eggs (ECEs). Each virus was inactivated and was used
for vaccine preparation with oil adjuvant (ISA70; Seppic, Paris, France).
For experiments, chickens were vaccinated intramuscularly with 0.5 ml
of inactivated oil emulsion vaccine. All experiments with live viruses
were performed in a biosafety level 3 containment facility at National
Veterinary Research and Quarantine Service in South Korea.
Sequence analysis. Viral RNAs were extracted using RNeasy mini
kit (QIAGEN, Valencia, CA) from infectious allantoic fluid from ECEs.
Standard reverse transcription-polymerase chain reaction (PCR) was
performed using One-Step RT-PCR kit (QIAGEN) with primers specific
for influenza virus as described Lee et al. (5). The sequences of CK/Kr/ES/
03 were deposited in the GenBank (see accession number in reference 5).
Chickens. In trial 1, 30 5-wk-old SPF chickens were divided into
three groups for protective efficacy test after one-dose vaccination of
each vaccine. Ten chickens were vaccinated one time with CK/Kr/ES/03
(H5N1) vaccine (H5N1-one). The other 10 chickens were vaccinated
one time with wbf/Kr/CMS2/02 (H5N3) vaccine (H5N3-one). The
remaining 10 chickens served as unvaccinated controls.
In addition, 24 5-wk-old SPF chickens were divided into three groups
for efficacy test with two doses injected at a 3-wk interval of each vaccine.
The chickens for the H5N1 two-dose vaccination group (H5N1-two)
and H5N3 two-dose vaccination group (H5N3-two) were vaccinated
with H5N1 and H5N3 vaccine, respectively. The chickens of each group
were vaccinated a second time 3 wk after the first vaccination. The
remaining eight chickens served as unvaccinated controls.
For protective efficacy test against H5N1 HPAI, chickens of each
group were challenged through intranasal route with 106.6 50% embryo
infectious dose (EID50)/0.1 ml CK/Kr/ES/03 (H5N1) virus at 3 wk
after once or twice vaccination. Clinical signs and mortality rates were
observed for 2 wk after lethal virus challenge. Swab samples were
collected at 2, 3, 5, and 7 days postchallenge from oropharynx and
cloacae for virus isolation in chicken embryo fibroblast cells.
In trial 2, the isolate Wbf/Kr/CSM2/02 (H5N3) was concentrated to
10 times (1024 HA unit) by centrifuging at 18,000 rpm for 3 hr.
Manipulation of inactivated vaccine containing the 1024 hemagglutinin
(HA) unit of virus and vaccination was done as described above to 10
12-wk-old chickens.
Serological analysis. Sera from vaccinated and challenged birds
were tested for detection of antibodies to the H5 by hemagglutination
inhibition (HI) test. For HI test, titers were determined using serial
twofold diluted sera with both of H5N1 and H5N3 antigens. NA
subtype-specific antibodies were detected with indirect immuno-
fluorescent antibody (IFA) assay. For IFA assay, the N1 protein of CK/
Kr/ES/03 (H5N1) was expressed using the BacPAK Baculovirus ex-
pression system (Clontech, Mountain View, CA) according to the
manufacturer’s instructions. Antigen for the IFA was prepared as follows
in that Spodoptera frugiperda (Sf21) cells were infected with recombinant
Table 1. Protective effect and antibody response in chickens after vaccination with the virus possessing homologous neuraminidase N1 and
heterologous neuraminidase N3 (trial 1).
Group Vaccination
HI titer
(log 2 6 SD)B
Results after challenge (%)A
Virus reisolationC
Clinical signs MortalityOropharynx Cloaca
H5N1-one OnceD 8.6 6 1.8 0/10E (0) 6/10 (60) 0/10 (0) 0/10 (0)
H5N3-one OnceF 2.7 6 1.9 6/10 (60) 6/10 (60) 6/10 (60) 5/10 (50)
Control Unvaccinated 0.0 6/10 (60) 10/10 (100) 10/10 (100) 10/10 (100)
H5N1-two TwiceG 11.7 6 0.6 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0)
H5N3-two TwiceH 7.8 6 1.2 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0)
Control Unvaccinated 0.0 8/8 (100) 8/8 (100) 8/8 (100) 8/8 (100)
AChallenge virus (A/CK/Korea/ES/03 (H5N1) with 106.6 EID50/bird) was administered intranasally.
BHI titers log 2 mean titer 6 SD after 3 wk after vaccination.
CSamples were collected at 2, 3, 5, and 7 days postchallenge.
DOnce vaccination of 5-wk-old chickens with 128 HA unit of A/CK/Korea/ES/03 (H5N1).
ENumber virus reisolation over number in group.
FOnce vaccination of 5-wk-old chickens with 64 HA unit of A/wild bird feces/Korea/CSM2/02 (H5N3).
GTwice vaccination at 5 and 8 wk with 128 HA unit of A/CK/Korea/ES/03 (H5N1).
HTwice vaccination at 5 and 8 wk with 64 HA unit of A/wild bird feces/Korea/CSM2/02 (H5N3).




(log 2 6 SD)B
Results after challenge (%)A
Virus reisolationC
Clinical signs MortalityOropharynx Cloaca
H5N3D 8.1 6 1.3 0/10E (0) 0/10 (0) 0/10 (0) 0/10 (0)
Control 0.0 10/10 (100) 10/10 (100) 10/10 (100) 10/10 (100)
AChallenge virus [A/CK/Korea/ES/03 (H5N1) with 106.6 EID50/bird] was administered intranasally.
BHI titers log 2 mean titer 6 SD after 3 wk after vaccination.
CSamples were collected at 2, 3, 5, and 7 days postchallenge.
DVaccination of 12-wk-old chickens with 1024 HA unit of A/wild bird feces/Korea/CSM2/02 (H5N3).
ENumber virus reisolation over number in group.
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baculovirus at a multiplicity of infection of 5. After 48 hr of inoculation at
28 C, cells were harvested and reacted with sera from vaccinated and
infected birds. Cells were observed for fluorescence after adding
a fluorescein isothiocyanate-conjugated anti-chicken IgG.
RESULTS AND DISCUSSION
Protection studies. The nucleotide homology of HA between
HPAI CK/Kr/ES/03 challenge strain and low pathogenic avian
influenza Wbf/Kr/CSM2/02 vaccine strain was 91.1%, whereas the
homology of NA gene between them was 54.6%. The amino acid
similarity of HA proteins between these viruses was 92.9%. The amino
acid sequences of cleavage site of HA protein were RERKKR/GLFGA
in CK/Kr/ES/03 and RETR/GLFGA in Wbf/Kr/CSM2/02 (H5N3).
In trial 1, the one dose of heterologous H5N3 vaccine group
(H5N3-one) showed relatively low protective efficacy compared with
the one dose of homologous H5N1 vaccine group (H5N1-one) after
challenge with H5N1 HPAI virus (Table 1). Mortality rate of H5N3-
one group was 50%, whereas that of H5N1-one group was 0%.
Neither H5N3-one nor H5N1-one group showed complete pro-
tective effect in virus shedding (101–103 50% tissue culture infective
dose [TCID50]/0.1 ml and 10
1 TCID50/0.1 ml, respectively). Unvac-
cinated control chickens showed 100% mortality and exhibited 60%
and 100% virus shedding in oropharynx and cloaca, respectively
(102–105 TICD50/0.1 ml). Although homologous H5N1 vaccine
induced more effective disease prevention results than that of het-
erologous H5N3 vaccine, the use of highly pathogenic strains has
safety restriction, especially in the commercial vaccine plant. Further-
more, H5N1 vaccine-induced antibodies were incapable of differen-
tiating from antibodies taken from chickens infected with the field
strain. Therefore, we investigated the possibility of a two-dose 3-wk
interval vaccination scheme to improve the protective efficacy of
heterologous H5N3 vaccine. The two doses of heterologous H5N3
vaccine as well as one dose of homologous H5N1 vaccine induced
complete protective effect in mortality and reduced virus shedding
completely against H5N1 HPAI virus challenge.
Finally, we tried to improve the efficacy of heterologous H5N3
vaccine with a one-dose vaccination scheme in trial 2. To increase
antigen quantity, viral antigen was concentrated to 10 times by
centrifugation. Chickens vaccinated with heterologous H5N3 vaccine
containing high antigen quantity (1024 HA unit) showed 100%
protection in mortality, and virus shedding was reduced completely
after H5N1 HPAI virus challenge after one dose of vaccination (Table
2). These results showed that one dose of 1024HA unit heterologous
H5N3 vaccine is a candidate vaccine for the preventing H5N1 HPAI.
Previous studies demonstrated that inactivated vaccines containing
the same HA subtype as the challenge virus protected the birds from
challenge regardless of the NA subtype (1,9). Moreover, they re-
ported that there was no positive correlation between the sequence
identity of the HA gene with range 96.8%–100% and the ability to
reduce the quantity of challenge virus shed, but there was a correlation
between the antigen quantity and all parameters of protection (9).
We obtained similar results in that although there was low sequence
identity between the vaccinated and challenged strain, the vaccinated
strain could protect birds challenged with HPAI virus. Therefore,
antigen quantity in the same HA subtype would be a more important
factor for protective efficacy of the vaccine.
Serological studies. The HI titers and IFA reactivity to re-
combinant N1 antigen are presented in Table 3. The HI titers of
chickens vaccinated with H5N1 were higher than those of the vac-
cinated group with H5N3 after vaccination (trial 1). Seroconversion
after challenge was evident in the group H5N1 challenge after H5N3
vaccination (v-H5N3, c-H5N1) compared with those of group H5N1
challenge after H5N1 vaccination (v-H5N1, c-H5N1). The HI titers
were higher using homologous viral HI antigen than heterologous
viral HI antigen. Chickens exhibited positive results in both the vacci-
nated and challenged group with H5N1 by using IFA assay to recombi-
nant N1 antigen. Thus, IFA assay with recombinant N1 would detect
H5N1-infected chickens without clinical signs after H5N3 vaccina-
tion. Accordingly, heterologous H5N3 vaccine would be a useful tool
for controlling epidemic HPAI in poultry caused by H5N1 virus.
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v-H5N1A 10 8.6 6 1.8 6.1 6 1.3 8/10B
v-H5N3C 10 2.7 6 1.9 4.3 6 2.3 0/10
v-H5N1,
c-H5N1D 10 9.2 6 0.8 7.1 6 0.9 10/10
v-H5N3,
c-H5N1E 5 7.4 6 1.1 8.8 6 1.3 5/5
Control 10 0.0 0.0 0/10
AChickens after 3-wk vaccination with CK/Kr/ES/03 (H5N1).
BNumber of positive reactivity over number in group.
CChickens after 3-wk vaccination with Wbf/Kr/CSM2/02 (H5N3).
DChickens challenged with CK/Kr/ES/03 (H5N1) after vaccination
with H5N1.
EChickens challenged with CK/Kr/ES/03 (H5N1) after vaccination
with H5N3.
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